LAURUS LABS vs MARKSANS PHARMA. - Comparison Results
Current Valuations
| LAURUS LABS | MARKSANS PHARMA. | LAURUS LABS / MARKSANS PHARMA. |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 89.1 | 28.5 | 313.0% | View Chart |
| P/BV | x | 18.4 | 4.9 | 374.9% | View Chart |
| Dividend Yield | % | 0.1 | 0.3 | 40.5% |
Financials
 LAURUS LABS  MARKSANS PHARMA. |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| LAURUS LABS Mar-26 |
MARKSANS PHARMA. Mar-26 |
LAURUS LABS / MARKSANS PHARMA. |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,141 | 271 | 421.6% | |
| Low | Rs | 517 | 156 | 331.4% | |
| Sales per share (Unadj.) | Rs | 126.2 | 65.1 | 193.8% | |
| Earnings per share (Unadj.) | Rs | 16.5 | 9.3 | 177.8% | |
| Cash flow per share (Unadj.) | Rs | 25.4 | 11.4 | 221.7% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0.90 | 222.2% | |
| Avg Dividend yield | % | 0.2 | 0.4 | 57.2% | |
| Book value per share (Unadj.) | Rs | 97.7 | 66.6 | 146.6% | |
| Shares outstanding (eoy) | m | 539.86 | 453.16 | 119.1% | |
| Bonus / Rights / Conversions | 0 | 0 | - | ||
| Price / Sales ratio | x | 6.6 | 3.3 | 200.5% | |
| Avg P/E ratio | x | 50.3 | 23.0 | 218.6% | |
| P/CF ratio (eoy) | x | 32.7 | 18.6 | 175.3% | |
| Price / Book Value ratio | x | 8.5 | 3.2 | 265.0% | |
| Dividend payout | % | 12.1 | 9.7 | 125.0% | |
| Avg Mkt Cap | Rs m | 447,528 | 96,660 | 463.0% | |
| No. of employees | `000 | NA | NA | - | |
| Total wages/salary | Rs m | 8,154 | 4,209 | 193.7% | |
| Avg. sales/employee | Rs Th | 0 | 0 | - | |
| Avg. wages/employee | Rs Th | 0 | 0 | - | |
| Avg. net profit/employee | Rs Th | 0 | 0 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 68,129 | 29,509 | 230.9% | |
| Other income | Rs m | 550 | 825 | 66.6% | |
| Total revenues | Rs m | 68,679 | 30,335 | 226.4% | |
| Gross profit | Rs m | 17,777 | 6,008 | 295.9% | |
| Depreciation | Rs m | 4,801 | 986 | 486.7% | |
| Interest | Rs m | 1,707 | 241 | 707.7% | |
| Profit before tax | Rs m | 11,819 | 5,606 | 210.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 2,920 | 1,405 | 207.9% | |
| Profit after tax | Rs m | 8,899 | 4,201 | 211.8% | |
| Gross profit margin | % | 26.1 | 20.4 | 128.2% | |
| Effective tax rate | % | 24.7 | 25.1 | 98.6% | |
| Net profit margin | % | 13.1 | 14.2 | 91.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 48,292 | 27,227 | 177.4% | |
| Current liabilities | Rs m | 36,354 | 5,271 | 689.7% | |
| Net working cap to sales | % | 17.5 | 74.4 | 23.5% | |
| Current ratio | x | 1.3 | 5.2 | 25.7% | |
| Inventory Days | Days | 29 | 3 | 1,035.5% | |
| Debtors Days | Days | 12 | 80 | 14.5% | |
| Net fixed assets | Rs m | 56,820 | 11,252 | 505.0% | |
| Share capital | Rs m | 1,080 | 453 | 238.3% | |
| "Free" reserves | Rs m | 51,671 | 29,745 | 173.7% | |
| Net worth | Rs m | 52,751 | 30,198 | 174.7% | |
| Long term debt | Rs m | 6,113 | 0 | - | |
| Total assets | Rs m | 105,112 | 38,479 | 273.2% | |
| Interest coverage | x | 7.9 | 24.2 | 32.7% | |
| Debt to equity ratio | x | 0.1 | 0 | - | |
| Sales to assets ratio | x | 0.6 | 0.8 | 84.5% | |
| Return on assets | % | 10.1 | 11.5 | 87.4% | |
| Return on equity | % | 16.9 | 13.9 | 121.3% | |
| Return on capital | % | 23.0 | 19.4 | 118.7% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 28.4 | 7.5 | 378.2% | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | 19,330 | 2,214 | 873.2% | |
| Fx inflow | Rs m | 43,470 | 13,267 | 327.7% | |
| Fx outflow | Rs m | 19,330 | 2,214 | 873.2% | |
| Net fx | Rs m | 24,140 | 11,053 | 218.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,235 | 4,581 | 354.4% | |
| From Investments | Rs m | -10,887 | -2,483 | 438.5% | |
| From Financial Activity | Rs m | -5,247 | -709 | 739.8% | |
| Net Cashflow | Rs m | 131 | 1,384 | 9.5% | |
Share Holding
| Indian Promoters | % | 27.5 | 43.9 | 62.6% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 41.7 | 23.7 | 176.4% | |
| FIIs | % | 28.0 | 17.5 | 160.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 72.5 | 56.1 | 129.2% | |
| Shareholders | 291,653 | 246,635 | 118.3% | ||
| Pledged promoter(s) holding | % | 2.7 | 0.0 | - |
Compare LAURUS LABS With: CIPLA DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
More on LAURUS LABS vs MARKSANS PHARMA.
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
LAURUS LABS vs MARKSANS PHARMA. Share Price Performance
| Period | LAURUS LABS | MARKSANS PHARMA. | S&P BSE HEALTHCARE |
|---|---|---|---|
| 1-Day | -0.89% | -1.67% | -0.49% |
| 1-Month | 17.59% | 22.59% | 1.88% |
| 1-Year | 107.86% | 77.87% | 13.88% |
| 3-Year CAGR | 66.91% | 41.59% | 21.95% |
| 5-Year CAGR | 20.97% | 35.14% | 14.11% |
* Compound Annual Growth Rate
Here are more details on the LAURUS LABS share price and the MARKSANS PHARMA. share price.
Moving on to shareholding structures...
The promoters of LAURUS LABS hold a 27.5% stake in the company. In case of MARKSANS PHARMA. the stake stands at 43.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of LAURUS LABS and the shareholding pattern of MARKSANS PHARMA..
Finally, a word on dividends...
In the most recent financial year, LAURUS LABS paid a dividend of Rs 2.0 per share. This amounted to a Dividend Payout ratio of 12.1%.
MARKSANS PHARMA. paid Rs 0.9, and its dividend payout ratio stood at 9.7%.
You may visit here to review the dividend history of LAURUS LABS , and the dividend history of MARKSANS PHARMA..
For a sector overview, read our pharmaceuticals sector report.
Today's Market
![]()
Sensex Today Trades Lower | Nifty Below 24,300 | Infosys & Titan Company Top Losers(10:30 am)
Sensex Today Trades Lower | Nifty Below 24,300 | Infosys & Titan Company Top LosersAsian equities were largely subdued on Monday as investors remained cautious about oil prices, which posted strong gains last week amid the absence of progress towards ending the Iran conflict, keeping concerns over inflation elevated.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
- Hidden Treasure
- Forever Stocks
- Big Wave Profits
- Equitymaster Venture
- Microcap Millionaires
- Momentum Profits
- Double Income
- Midcap Value Alert
- Exponential Profits
- Annual Breakout Alert
- Lazy Millionaire
- Phase One Alert
- InsiderPro Stocks
- StockSelect
- Private Briefing
- Active Wealth Multiplier 2030
- FundSelect
- Fund Advantage
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
- Best Defence Stocks in India
- Upcoming Dividend Stocks
- Best Semiconductor Stocks in India
- Data Center Stocks in India
- Best Railway Stocks in India
- Best Solar Stocks in India
- Fastest Growing Stocks in India
- List of BSE Sensex 30 Stocks
- Adani Group Shares
- Stocks Recently Bought by FIIs in India
- Top Value Stocks in India
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.
Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.
The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here.